Selzentry (maraviroc) / ViiV Healthcare - LARVOL DELTA

CCR5 blockade inhibits menstrual-driven proinflammatory T cell infiltration into the cervicovaginal mucosa of women. (PubMed, Sci Adv) - "Across the menstrual cycle, we identified dynamic changes consistent with an immune response during the time frame of progesterone withdrawal. Notably, maraviroc treatment in women led to prolonged receptor antagonism, substantially reducing this immune response. These data demonstrate that menstrual-driven proinflammatory CD4 T cell infiltration into the FRT can be inhibited by CCR5 blockade, which may provide an immunomodulatory approach to treating associated diseases and conditions affecting women."

Journal • Infectious Disease • Inflammation • CD4

PD-L1 antibody-induced cardiac dysfunction is regulated by CCR5-positive macrophages. (PubMed, Eur J Pharmacol) - "Notably, although maraviroc failed to potentiate the anti-tumor effect of PD-L1 therapy, it effectively attenuated the PD-L1-associated myocardial toxicity without diminishing the anti-tumor response in melanoma-bearing mice. These findings delineate a CCL5/CCR5 axis as the central mechanism underlying early PD-L1-induced cardiotoxicity, while establishing CCR5 blockade as a translatable strategy for preventing immunotherapy-associated cardiac complications, with maraviroc demonstrating pleiotropic protective effects spanning immune modulation, metabolic reprogramming, and apoptosis control."

Journal • Cardiovascular • Immune Modulation • Immunology • Melanoma • Oncology • Solid Tumor • CCR5 • HIF1A • ITGAM • PKM • PTPRC

Maraviroc Attenuates Orbital Remodeling, Inflammation, and Lipid Dysregulation in a Murine Model of Thyroid Eye Disease. (ETA 2026) - "Maraviroc emerges as a promising targeted therapeutic strategy for TED, exerting anti-inflammatory and anti-adipogenic effects while largely sparing thyroid autoimmunity. These preclinical findings provide a strong rationale for further clinical investigation of maraviroc as a potential treatment for TED. Data previously published in: [Front."

Preclinical • Endocrine Disorders • Grave’s Disease • Immunology • Inflammation • Metabolic Disorders • Ocular Inflammation • Ophthalmology • Thyroid Eye Disease • CD4 • TSHR

Maraviroc Inhibits SARS-CoV-2 Through Variant-Dependent Effects on Viral Entry and Mpro Activity Using Single-Round Infectious Particle and Virus-like Particle Models. (PubMed, Viruses) - "Collectively, these findings demonstrate that MVC exerts variant-dependent antiviral effects by targeting viral entry, modulating trafficking pathways, and inhibiting Mpro activity. This study highlights MVC as a multi-stage inhibitor with differential efficacy against SARS-CoV-2 variants, providing insights into its potential therapeutic application."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Identification of Isoliensinine as a Novel CCR5 Inhibitor for the Prevention of Skeletal Muscle Atrophy Through Virtual Screening and Experimental Validation. (PubMed, Molecules) - "To identify potential CCR5 inhibitors, a database of 7860 natural alkaloids was constructed for pharmacophore-based virtual screening using the CCR5-Maraviroc crystal structure...In vitro, ISO dose-dependently inhibited CCL11-induced CCR5 activity (IC50 = 1.314 μM) with low cytotoxicity in C2C12 myotubes, and markedly alleviated CCL11-induced myotube atrophy by suppressing CCR5 activation and the upregulation of the muscle atrophy-related markers MAFbx and MuRF1. These findings provide preliminary evidence for ISO as a potential CCR5-targeting candidate for further investigation in sarcopenia."

Journal • Muscular Atrophy • Sarcopenia • CCL11

Cytotoxic CD4+ T cells induce age-associated myelopoiesis through CCL5-CCR5 signaling. (PubMed, Nat Aging) - "Pharmacological blockade of CCR5 using the Food and Drug Administration-approved drug maraviroc normalizes myelopoiesis, reduces circulating and tissue-infiltrating neutrophils, and improves multiple aging-related biomarkers and functional outcomes in aged mice. Together, these findings demonstrate a T cell-bone marrow axis that exacerbates age-associated decline and highlight CCR5 inhibition as a potential geroprotective strategy."

IO biomarker • Journal • CD4 • STING

Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Antiretrovirals (clinicaltrials.gov) - P2 | N=70 | Recruiting | Sponsor: Federal University of So Paulo | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2027 ➔ Jun 2028

Enrollment open • Trial completion date • Human Immunodeficiency Virus • Infectious Disease • CD4 • IL4

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... (clinicaltrials.gov) - P1/2 | N=265 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2027 ➔ Jul 2028 | Trial primary completion date: Jul 2026 ➔ Jul 2027

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • B Cell Lymphoma • Bone Marrow Transplantation • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • Graft versus Host Disease • Hematological Malignancies • Human Immunodeficiency Virus • Immunology • Infectious Disease • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Oncology • Transplantation • IGH

CKLF1 Upregulation Exacerbates Secondary Brain Injury after Intracerebral Hemorrhage by Promoting Neuronal Ferroptosis and Oxidative Stress. (PubMed, Free Radic Biol Med) - "The present study identifies CKLF1 as a previously unrecognized regulator of neuronal ferroptosis following ICH through the CCR5/p38/p53 signaling pathway. These findings provide new mechanistic insights into ICH pathogenesis and highlight CKLF1 as a promising therapeutic target for precision treatment of hemorrhagic stroke."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Inflammation • Vascular Neurology • ACSL4 • GPX4 • SLC7A11

EcoXAI: Autonomous Agentic Ecosystem for Explainable Artificial Intelligence and Biomedical Discovery. (PubMed, bioRxiv) - "In our use case in drug repurposing for Alzheimer's Disease, EcoXAI evaluated 103 drug candidates and identified 79 novel candidates whose predictive models exceeded a randomized baseline, including the CCR5 antagonist Maraviroc, whose generated hypothesis was subsequently supported by the literature...EcoXAI is available on GitHub at: https://github.com/EpistasisLab/EcoXAI . [email protected]."

Journal • Alzheimer's Disease • CNS Disorders

Integrated virtual screening and molecular dynamics reveal novel Maraviroc analogues as optimized CCR5 entry inhibitors for HIV-1. (PubMed, J Mol Graph Model) - "These simulations demonstrated that while some analogues show improved predicted toxicological profiles, they often incur significant thermodynamic penalties or higher structural drift than Maraviroc. These results highlight ZINC001542979606 and ZINC000030691387 as theoretical leads that require in vitro validation to navigate the complex trade-offs involved in developing safer HIV-1 entry inhibitors."

Journal • Human Immunodeficiency Virus • Infectious Disease

HIV T cell polyfunctionality in combined therapeutic interventions to decrease HIV reservoir size (AIDS 2026) - " Within a randomized clinical trial (NTC 02961829), antiretroviral (ART)-suppressed participants were allocated to different intervention arms, including a control group (ART), ART intensification with dolutegravir plus maraviroc (ART Int), ART intensification + LRA (nicotinamide, maraviroc), and ART intensification + anti-proliferative agent (auranofin). In ART-suppressed individuals, HIV-specific T cell responses showed limited polyfunctionality. Nicotinamide was associated with a transient increase in dual IFN-?+TNF-a+ T cells, while other interventions did not modulate polyfunctional responses. These findings provide an important baseline for future studies exploring strategies to enhance the functional quality of HIV-specific T cells, aiming for HIV control without ART."

Human Immunodeficiency Virus • Infectious Disease • CD4 • CD8 • IL2 • TNFA

Integrated machine learning and molecular dynamics-driven multi-target virtual screening of FDA-approved drugs for drug repurposing in breast cancer. (PubMed, In Silico Pharmacol) - "Ponatinib emerged as the top-ranked computational candidate (mean: - 10.07 kcal/mol), followed by Regorafenib (- 9.64), Sorafenib (- 9.46), and Entrectinib (- 9.45), while non-oncology drugs including antrafenine, betrixaban, and maraviroc demonstrated novel multi-target binding profiles...MM-GBSA calculations revealed a binding hierarchy concordant with docking scores (R2 = 0.92): Ponatinib-VEGFR2 (ΔGbind = - 42.38 kcal/mol) > Entrectinib-CDK6 (- 38.56) > Ponatinib-EGFR (- 33.24) > Entrectinib-HER2 (- 28.47) > Dacomitinib-HDAC3 (- 24.63 kcal/mol)...As the present study is entirely computational, the identified compounds should be regarded as hypothesis generating leads requiring experimental validation through in vitro kinase and HDAC3 inhibition assays, cell based studies, and target engagement confirmation before any translational conclusions can be drawn. The online version contains supplementary material available at..."

FDA event • Journal • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • CDK6 • EGFR • HDAC3 • HER-2 • KDR

Pharmacophore-based identification and molecular docking of CCR5 inhibitors: insights from dynamic simulations. (PubMed, J Recept Signal Transduct Res) - "A ligand-based pharmacophore model was generated using the Pharmit server, with Maraviroc as a reference molecule...MD simulation confirmed its stability, with RMSD fluctuations between 0.20-0.38 nm, low RMSF deviations in active site residues, and a compact radius of gyration (∼2.48 nm) compared to apo-CCR5. The integrated computational approach identified ZINC000000867238 as a potent and stable CCR5 inhibitor candidate, warranting further in vitro and in vivo validation as a potential HIV-1 entry blocker."

Journal • Human Immunodeficiency Virus • Infectious Disease

Maraviroc attenuates inflammation-exacerbated cognitive and amyloid pathology in an early-stage Alzheimer's disease mouse model. (PubMed, Transl Psychiatry) - "In this model, maraviroc is associated with modulation of glial inflammatory responses, reduced pro-inflammatory cytokine levels, and alleviation of amyloid pathology in the hippocampus, which together coincide with improved cognitive performance. Figure created with BioRender.com."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Human Immunodeficiency Virus • Infectious Disease • Inflammation • GFAP

Maraviroc for Stroke Recovery (MASTER): protocol and status of a phase 2 double-blind placebo-controlled randomized clinical trial (EAN 2026) - "MASTER explores a novel pharmacological approach to enhance post-stroke motor recovery and to investigate its underlying mechanisms with the help of advanced MRI."

Clinical • P2 data • Cardiovascular • Ischemic stroke

Tumor-educated macrophages promote cytokine-driven lung colonization in triple-negative breast cancer. (PubMed, Oncoimmunology) - "Pharmacological inhibition of CCR5, CXCR2, and IL1R1 with maraviroc, navarixin, and anakinra, respectively, disrupted this cytokine axis, suppressing metastatic colonization in vivo. Our findings reveal that blocking cytokine receptor signaling disrupts the pro-metastatic crosstalk between macrophages and TNBC cells, offering a clinically actionable strategy to restrain metastasis and overcome therapy resistance in TNBC."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CCL3 • CD4 • FOXP3 • IL1B • IL1R1

Anti-inflammation Treatment for Idiopathic Inflammatory Myopathies (clinicaltrials.gov) - P4 | N=10 | Not yet recruiting | Sponsor: Chinese University of Hong Kong

New P4 trial • Immunology • Inflammation • Myositis

IMPACT-LC: A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID (clinicaltrials.gov) - P2/3 | N=252 | Not yet recruiting | Sponsor: HealthBio, Inc. | Trial completion date: Apr 2026 ➔ May 2027 | Trial primary completion date: Feb 2026 ➔ Dec 2026

Head-to-Head • Trial completion date • Trial primary completion date • Novel Coronavirus Disease

CCR5 and CD74 are potential therapeutic targets for necroinflammation in preclinical cholesterol crystal embolism. (PubMed, Sci Transl Med) - "Pharmacological inhibition of CCR5 or CD74 using maraviroc or milatuzumab, respectively, as well as their combined administration before CC injection, reduced vascular thrombosis and tissue damage without raising bleeding risk in the C57BL/6J mouse CCE model. Even when treatment was delayed by 2 hours postembolism, it still decreased complications like thrombotic angiopathy and AKI upon CCE. These findings highlight CCR5 and CD74 as potential therapeutic targets for CCE-related necroinflammation."

Journal • Preclinical • Acute Kidney Injury • Atherosclerosis • Cardiovascular • Hematological Disorders • Inflammation • Nephrology • Renal Disease • Thrombosis • CCR5 • CD74 • MIF

Cellular context and ligand class shape CXCR4-CCR5 heteromerization in live cells. (PubMed, Res Sq) - "Agonists induced transient heteromerization coupled to receptor internalization, while antagonists, especially plerixafor together with maraviroc, stabilized persistent surface-associated complexes. Molecular dynamics simulations in asymmetric bilayers resembling MDA-MB-231 and MCF-10A membranes identified cholesterol-enriched receptor interfaces that prolong CXCR4-CCR5 dimer lifetimes in MDA-like membranes. These results show that GPCR heteromerization is not an intrinsic fixed property of receptor pairs, but an emergent behavior shaped by cell state, lipid environment, and ligand input."

Journal • Oncology • CXCR4

C-C motif chemokine 3 interferes with oligodendrocyte maturation in the brain. (PubMed, Biochem Biophys Res Commun) - "These abnormalities were ameliorated by maraviroc treatment. Collectively, CCL3 interferes with oligodendrocyte maturation, thereby delaying axonal myelination and resulting in neural circuit dysfunction mediated by VPA."

Journal • Autism Spectrum Disorder • Genetic Disorders • Solid Tumor • CCL3 • MBP

Efficacy and Safety of Different GVHD Prophylaxis Regimens for Unrelated Donor Hematopoietic Stem Cell Transplantation: A Real-World Long-Term Retrospective Study (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi) - "This study concludes that among high-risk AML/MDS patients receiving unrelated-HSCT, an ATG-based regimen for GVHD prophylaxis can effectively reduce the incidence and recurrence rate of acute GVHD, improve GRFS, and should be considered as the preferred strategy."

Journal • Real-world evidence • Retrospective data • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation

Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals (clinicaltrials.gov) - P2 | N=70 | Not yet recruiting | Sponsor: Federal University of São Paulo | Trial primary completion date: Jul 2026 ➔ Jan 2027

Trial primary completion date • Human Immunodeficiency Virus • Infectious Disease • CD4 • IL4

Maraviroc alleviates neuropathic pain symptoms in a mouse model of spared nerve injury. (PubMed, Mol Pharmacol) - "SIGNIFICANCE STATEMENT: Spared nerve injury-induced neuropathic pain is associated with upregulation of the C-C motif chemokine ligand 5. Targeting the C-C motif chemokine ligand 5-CCR5 axis with FDA-approved maraviroc alleviated pain phenotype through modulating different pathways in male and female mice."

Journal • Preclinical • Human Immunodeficiency Virus • Immunology • Infectious Disease • Neuralgia • Pain